NASDAQ:QNRX

Quoin Pharmaceuticals Q2 2025 Earnings Results & Report

Quoin Pharmaceuticals logo
$3.56 +0.20 (+5.95%)
Closing price 04:00 PM Eastern
Extended Trading
$3.63 +0.07 (+1.94%)
As of 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Quoin Pharmaceuticals beat analyst earnings expectations in its Q2 2025 results, released August 7, 2025. The company reported EPS of -$6.28 versus the -$6.83 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Quoin Pharmaceuticals EPS Results

Actual EPS
-$6.28
Consensus EPS
-$6.83
Beat/Miss
Beat by +$0.55
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Quoin Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quoin Pharmaceuticals Q2 2025 Earnings FAQ

Quoin Pharmaceuticals (NASDAQ:QNRX) reported earnings of -$6.28 per share for Q2 2025, beating the consensus estimate of -$6.83. The report was announced on Thursday, August 7, 2025.

Quoin Pharmaceuticals Earnings Headlines

Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Rating Lowered by Wall Street Zen
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Quoin Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quoin Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quoin Pharmaceuticals and other key companies, straight to your email.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical-stage pharmaceutical company focused on developing treatments for rare and orphan diseases, with an emphasis on conditions affecting the skin.

Its lead investigational product, QRX003, is a topical therapy being developed for Netherton syndrome, a rare genetic skin disorder. The company has also described plans to explore the treatment’s potential in other skin conditions. QRX003 is investigational and has not been established as a proven treatment.

View Quoin Pharmaceuticals Profile